Adalimumab & Infliximab Remain in Newborns after Delivery

In the study, the authors discussed how the prolonged clearance of adalimumab and infliximab may have a significant clinical impact when planning for live vaccines, and recommend that live vaccines be postponed until after one year of age for infants born to mothers receiving these agents. The authors also found no increased risk of adverse pregnancy outcomes, which is consistent with previous studies.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. 2016 Apr 8. pii:S0016–5085(16):30054-3. doi: 10.1053/j.gastro.2016.04.002. [Epub ahead of print]

How to minimize the risks of pregnancy for women with SLE

A recent study in The Journal of Rheumatology sheds light on the importance of preconceptional cardiovascular health in women with systemic lupus erythematosus. Although many questions remain, improved cardiovascular health measures seem to positively affect pregnancy outcomes, suggesting a potential role for preconception cardiovascular interventions.1 Women with lupus now have healthier pregnancies than in the…

A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

NEW YORK (Reuters Health)—New registry data should help reassure women with Crohn’s disease (CD) who need to continue infliximab during pregnancy that it won’t harm their baby. “The clinical condition of infants born to women with gestational infliximab exposure was similar to those without exposure,” the study team reports online July 19 in the American…

A Better Family Plan

Study Says Mothers’ Cardiovascular Health Is Linked to Pregnancy Outcomes in Lupus

Treat to Target: Rheumatoid Arthritis in Pregnant Patients

Study Supports Safety of Infliximab in Pregnancy

Related Articles